Implementation of the Meningitis Vaccine Project in Africa: lessons for vaccine implementation programs

Autor: Thomas Lear, Obidimma C Ezezika, Meron Mengistu

Publikováno v: Journal of Global Health Reports, Vol 5 (2021)

Background The Meningitis Vaccine Project (MVP) was an international partnership that began in 2010 and focused on the development, testing, licensure, and widespread introduction of a conjugate vaccine with the promise of protecting millions of live

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d14aa8b1a7bcc9ae81a2909d9df89bea
https://joghr.scholasticahq.com/article/29042-implementation-of-the-meningitis-vaccine-project-in-africa-lessons-for-vaccine-implementation-programs.pdf

Lessons from the Meningitis Vaccine Project

Autor: Mamoudou Harouna Djingarey, F. Marc LaForce, Marie-Pierre Preziosi, Simonetta Viviani

Publikováno v: Viral Immunology. 31:109-113

From 2001 to 2017 the Meningitis Vaccine Project (MVP), a Gates Foundation funded partnership between PATH and the World Health Organization (WHO), successfully developed, tested, licensed, and introduced an affordable new Group A meningococcal conju

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbcf7826eec7f88734504c756a48b3af
https://doi.org/10.1089/vim.2017.0120

Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials

Autor: Beate Kampmann, Aldiouma Diallo, Ray Borrow, Samba O. Sow, Caroline Trotter, Olubukola T. Idoko, Michael T. White

Publikováno v: The Lancet Infectious Diseases
The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2019, 19 (3), pp.327-336. ⟨10.1016/S1473-3099(18)30674-1⟩
The Lancet Infectious Diseases, 2019, 19 (3), pp.327-336. ⟨10.1016/S1473-3099(18)30674-1⟩

Summary Background A meningococcal group A conjugate vaccine, PsA-TT (also known as MenAfriVac), was developed with the support of the Meningitis Vaccine Project. Around 280 million individuals aged 1–29 years have been immunised across the African

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e0afa837b7e000a2d1d103f3b158ad0
https://www.repository.cam.ac.uk/handle/1810/289784

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

Autor: Olubukola T. Idoko, Aldiouma Diallo, Enricke Bouma, Adebayo Akinsola, Abraham Hodgson, Fadima Cheick Haidara, Samba O. Sow, Marie-Pierre Preziosi, Bou Diarra, Godwin Enwere, Beate Kampmann, Patrick Ansah

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Background. The Meningitis Vaccine Project (MVP) was established to address epidemic meningitis as a public health problem in sub-Saharan Africa and, to that end, worked to develop a group A meningococcal conjugate vaccine, PsA-TT. Methods. Experienc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbb3373192b4e2ff443739051be8cba1
https://doi.org/10.1093/cid/civ596

Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali

Autor: Kelly Townsend, Ray Borrow, Awa Traoré Eps Dembélé, Xilian Bai, Samba O. Sow, Uma Onwuchekwa, Nicole E. Basta, Helen Findlow, Abdoulaye Berthe, Rahamatou Moustapha Boukary, Lesley Mabey

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Efforts to prevent the large-scale outbreaks of meningococcal disease that have led to significant morbidity and mortality in the African meningitis belt, a region stretching from Senegal to Ethiopia, changed dramatically in 2010 when a newly develop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::667a98fddb0e5def127ae21a4aa38c1e
https://doi.org/10.1093/cid/civ602